Cannara Biotech (CNSX:LOVE – Get Free Report) had its price objective increased by stock analysts at TD from $3.25 to $4.00 in a research note issued on Thursday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock.
Separately, Haywood Securities set a $3.00 price objective on Cannara Biotech and gave the company a “buy” rating in a research note on Monday, April 6th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $3.42.
View Our Latest Report on LOVE
Cannara Biotech Stock Performance
About Cannara Biotech
Cannara Biotech Inc is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec’s low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands.
See Also
- Five stocks we like better than Cannara Biotech
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Cannara Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannara Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
